A Phase 3 Master Protocol to evaluate additional dose(s) of BNt162b2 in healthy 12 to 30 year old individuals previously vaccinated with BNt162b2
A Phase 3 Master Protocol to evaluate additional dose(s) of BNt162b2 in healthy 12 to 30 year old individuals previously vaccinated with BNt162b2